L. Myers

Benefit-risk assessment for brincidofovir for the treatment of smallpox: U.S. Food and Drug Administration's Evaluation.

Yu Cao, K. Chan-Tack, K. Struble, 2021, Antiviral research.

Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox.

K. Chan-Tack, P. Harrington, S. Seo, 2019, The Lancet. Infectious diseases.

Consensus on the Key Characteristics of Immunotoxic Agents as a Basis for Hazard Identification

Andrew A. Rooney, L. Zeise, C. McHale, 2022, Environmental health perspectives.

Is It Adverse, Nonadverse, Adaptive, or Artifact?

P. Mann, T. Steinbach, A. Pandiri, 2017, Toxicologic pathology.

Naturally occurring infections in non-human primates (NHP) and immunotoxicity implications: Discussion sessions

K. Mansfield, N. Lerche, J. Simmons, 2010, Journal of Immunotoxicology.